<DOC>
	<DOCNO>NCT00654368</DOCNO>
	<brief_summary>The purpose study evaluate use etanercept treatment rheumatoid arthritis without methotrexate treatment 24 month period</brief_summary>
	<brief_title>CAMEO : Canadian Methotrexate Etanercept Outcome Study</brief_title>
	<detailed_description>This noninferiority study multicenter , open-label , randomized trial patient rheumatoid arthritis ( RA ) . Patients adequate response methotrexate ( MTX ) etanercept ( 50 mg/week subcutaneously [ SC ] ) add exist MTX therapy least 15 mg/week ( 10 mg/week case document intolerance high dos MTX ) baseline follow 6 month . After 6 month therapy , participant randomize 1:1 ratio one 2 treatment arm : either discontinue MTX ( taper 6 week ) continue etanercept alone continue etanercept plus MTX additional 18 month .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>18 year age old baseline visit An American College Rheumatology ( ACR ) diagnosis rheumatoid arthritis onset symptom least 6 month Active disease least 3 swollen joint Disease Activity Severity 28 baseline visit A Disease Activity Severity 28 score â‰¥ 3.2 baseline visit Have previously receive etanercept therapy Able start etanercept therapy per approve product monograph Able continue methotrexate therapy per approve product monograph receive dose least 15 mg/wk ( 10 mg/wk case document intolerance high dos ) least 12 week dose stable least 4 week baseline visit The patient legally acceptable representative must provide write informed consent participation study study specific procedure perform Patients positive purified protein derivative ( PPD ) skin test document course antituberculosis therapy . Patients positive PPD skin test ( equal great 5 mm ) , negative chest xray screen repeat indicated study , low risk base exposure travel initiate course antituberculosis therapy least 8 week complete would eligible study . The full course antituberculosis therapy must complete Patients previously receive infliximab adalimumab Active infection within 2 week baseline visit study period Any history human immunodeficiency ( HIV ) infection , untreated tuberculosis , multiple sclerosis , congestive heart failure , hepatitis B , hepatitis C , cytopenia , prior current use cyclophosphamide malignancy ( basal cell carcinoma squamous cell carcinoma skin , situ carcinoma cervix ) past 5 year Women pregnant lactate childbearing potential use adequate contraception Receipt investigational therapy within 4 week initiation study medication study period Presence significant uncontrolled medical condition , investigator 's opinion precludes use etanercept , outlined product monograph Participants available followup assessment unable comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Amgen</keyword>
</DOC>